Management Comment The second pivotal trial PROMISE 2 commenced in November of 2016 and is evaluating the safety and efficacy of eptinezumab administered via infusion once every twelve weeks for six months in approximately 1050 patients with chronic migraine.

~ Earnings call 4q 2016